LIPID, CARE trials: Pravastatin improves post-AMI survival
LIPID, CARE trials: Pravastatin improves post-AMI survival
Drug reduces risk of repeat heart attack, too
The world’s largest and longest-running heart trial, the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, shows heart attack survival rates are increased by almost a quarter with pravastatin (Bristol-Myers Squibb’s Pravachol).
Researchers compared the effects of the cholesterol-lowering medication (40 mg/day) with those of placebo over a period of six years in 9,000 patients ranging in age from 31 to 75.1 The study results demonstrate that the agent plays an important role in reducing death from a second heart attack and stroke in heart attack survivors. Pravastatin:
• reduced total deaths by 22%;
• reduced deaths from coronary heart disease by 24%;
• reduced the total number of heart attacks by 29%;
• reduced stroke by 19%.
Originally designed to be a seven-year study, LIPID was stopped early because of compelling evidence that patients treated with pravastatin derived significant benefits compared to patients taking placebo.
Study participants had a history of myocardial infarction or hospitalization for unstable angina and had cholesterol levels of 155-271 mg/dL. Both placebo and medication groups received advice on following a cholesterol-lowering diet. Death from coronary heart disease occurred in 8.3% of the patients in the placebo group and 6.4% of those in the pravastatin group. The incidence of all cardiovascular outcomes — AMI, death from coronary heart disease or nonfatal myocardial infarction, stroke, and coronary revascularization — was consistently lower among patients assigned to receive pravastatin.
Of patients who survive heart attacks, two-thirds typically suffer a second within seven to 13 months. In a related study, the cholesterol and recurrent events (CARE) trial, pravastatin was shown to reduce the risk of repeat cardiac events among women who have already had heart attacks.2
Researchers studied a group of nearly 600 postmenopausal women who had heart attacks three to 20 months earlier. All participants had cholesterol levels less than 240 mg/dL with LDL levels between 115 and 174. One group took pravastatin 40 mg/day for five years; the other group took a placebo. After one year, the risk of coronary events, including fatal and nonfatal heart attack and stroke for the medication group dropped by half.
Pravastatin is generally well-tolerated. Most common side effects are headaches, rash, and gastrointestinal disturbances.
Out of the recent 71st scientific session of the Dallas-based American Heart Association, come results of another trial underlining the benefits of cholesterol-reduction.
The AVERT (Atorvastatin Versus Revascular-ization Treatments) trial demonstrated that aggressive LDL reduction to levels below 100 mg/dL delays the first ischemic event and decreases need for revascularization.
AVERT enrolled 341 patients with stable coronary artery disease — all candidates for angioplasty — and randomized them to either atorvastatin (Parke Davis/Pfizer’s Lipitor) 80 mg/day or angioplasty. About 87% of patients on atorvastatin in the 18-month study were able to avoid revascularization during 18 months of follow up.
During follow up, patients on the lipid-lowering therapy had a 36% reduction in coronary events compared with angioplasty patients, with events occurring in 13% of atorvastatin patients and in 21% of angioplasty patients.
References
1. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1,349-1,357.
2. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. JACC 1998; 32:140-146.
PORT IHD study available
You can order the Agency for Health Care Policy and Research’s final report on ischemic heart disease by calling the AHCPR Clearinghouse at (800) 358-9295. Outcome Assessment Program for Ischemic Heart Disease: Patient Outcomes Research Team (PORT) Report, a 72-page report, AHCPR publication No. 98-N003, is free while supplies last.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.